On 25 March, Ergomed announced their Audited Full Year Results for 2019 showing that the year had been transformational for the company, with revenue of £68.3m (up 26.1%), adjusted EBITDA of £12.5m (up from £2.3m in 2018), an order book of future contracted revenue of £124.1m (up 13.6%) and a new £30m credit facility. Additonally, […]

On 25 March, Ergomed announced their Audited Full Year Results for 2019 showing that the year had been transformational for the company, with revenue of £68.3m (up 26.1%), adjusted EBITDA of £12.5m (up from £2.3m in 2018), an order book of future contracted revenue of £124.1m (up 13.6%) and a new £30m credit facility.

Additonally, Ergomed has their announced involvement in a study at the Papa Giovanni XXIII Hospital in Bergamo, Italy where the siltuximab antibody is being trialed in the treatment of patients with serious respiratory complications caused by COVID-19.

The strong financial results, in addition to the news of Ergomed’s provision of clinical research services for the COVID-19 study, were discussed when Proactive Investors’ Andrew Scott spoke with Ergomed’s Chief Financial Officer, Richard Barfield and Head of Clinical Development, Dr Gordana Tonkovic.

 

This site uses cookies to personalize and customize your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.


  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Secured By miniOrange